Guardant Health
Our Tests

Liquid biopsy for every stage of the cancer journey.

From early detection to therapy selection to recurrence monitoring — Guardant Health's portfolio delivers actionable genomic intelligence from a simple blood draw.

Therapy Selection

Guardant360

Advanced Solid Tumor Testing

SpecimenBlood draw (2 × 10 mL tubes)
TAT7 business days
Order Guardant360

The most comprehensive liquid biopsy for advanced solid tumors.

Guardant360 analyzes 74 genes from circulating tumor DNA to identify actionable alterations, resistance mechanisms, and microsatellite instability — enabling oncologists to match patients with targeted therapies and immunotherapies.

Clinical IndicationPatients with advanced solid tumors requiring therapy selection or monitoring

Key Features

74-gene comprehensive panel
SNVs, indels, CNAs, fusions, MSI, TMB
Validated in 100+ tumor types
FDA-approved companion diagnostic
Early Detection

Shield

Colorectal Cancer Screening

SpecimenBlood draw (1 × 10 mL tube)
TAT10 business days
Order Shield

A blood test for colorectal cancer screening.

Shield is a blood-based colorectal cancer (CRC) screening test for average-risk adults aged 45 and older. It detects CRC at early, more treatable stages — offering a non-invasive alternative for patients who decline colonoscopy.

Clinical IndicationAverage-risk adults aged 45+ for colorectal cancer screening

Key Features

FDA-approved for CRC screening
83% sensitivity for CRC
90% specificity
Non-invasive blood draw only
Recurrence Monitoring

Guardant Infinity

Minimal Residual Disease

SpecimenBlood draw (2 × 10 mL tubes) + tumor tissue
TAT14 business days
Order Guardant Infinity

Detect residual disease before clinical relapse.

Guardant Infinity is a personalized MRD (minimal residual disease) test that detects circulating tumor DNA after curative-intent treatment. It enables earlier intervention by identifying molecular recurrence weeks to months before imaging.

Clinical IndicationPost-surgical monitoring for patients treated with curative intent

Key Features

Personalized tumor-informed design
Detects recurrence 6–12 months earlier than imaging
Validated across multiple solid tumor types
Longitudinal monitoring support
Surveillance

Guardant Reveal

Early-Stage Monitoring

SpecimenBlood draw (2 × 10 mL tubes)
TAT10 business days
Order Guardant Reveal

Surveillance for early-stage cancer patients.

Guardant Reveal is a tissue-agnostic MRD test for early-stage cancer patients. It uses a tumor-naïve approach — no tissue required — making it accessible for patients where tissue is unavailable or insufficient.

Clinical IndicationEarly-stage solid tumor patients post-treatment surveillance

Key Features

Tissue-naïve — no tumor sample required
Broad tumor type coverage
Methylation + fragmentomics approach
Accessible for all early-stage patients
How to Order

Ordering is simple.

01

Select your test

Choose the appropriate Guardant test based on your patient's clinical indication and stage of care.

02

Submit a requisition

Complete the online requisition form or contact your Guardant Health representative for assistance.

03

Collect the sample

A simple blood draw at your facility. Guardant provides collection kits and shipping materials.

04

Receive your report

Comprehensive genomic report delivered to your portal within the stated turnaround time, with clinical interpretation support.